Latham & Watkins LLP represented Atea Pharmaceuticals in the transaction, while Davis Polk advised the representatives of the underwriters. Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”) has…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
